What is B. Riley's Estimate for TG Therapeutics Q3 Earnings?

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at B. Riley boosted their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a report issued on Monday, May 5th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings of $0.40 per share for the quarter, up from their previous estimate of $0.26. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2026 earnings at $1.50 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.67 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.07) earnings per share.

Several other equities research analysts also recently weighed in on TGTX. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Stock Performance

TG Therapeutics stock traded down $0.22 during mid-day trading on Thursday, reaching $33.64. 2,237,034 shares of the company were exchanged, compared to its average volume of 3,022,129. The firm's 50-day simple moving average is $38.90 and its two-hundred day simple moving average is $33.63. TG Therapeutics has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a market cap of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently made changes to their positions in the stock. Deutsche Bank AG increased its holdings in TG Therapeutics by 1.1% in the first quarter. Deutsche Bank AG now owns 148,705 shares of the biopharmaceutical company's stock valued at $5,863,000 after buying an additional 1,685 shares in the last quarter. WealthShield Partners LLC purchased a new position in TG Therapeutics in the 1st quarter valued at approximately $239,000. Thoroughbred Financial Services LLC acquired a new position in TG Therapeutics during the first quarter worth $324,000. PNC Financial Services Group Inc. raised its holdings in TG Therapeutics by 27.0% during the first quarter. PNC Financial Services Group Inc. now owns 9,019 shares of the biopharmaceutical company's stock worth $356,000 after purchasing an additional 1,916 shares during the last quarter. Finally, Commerce Bank boosted its position in TG Therapeutics by 33.9% during the first quarter. Commerce Bank now owns 9,093 shares of the biopharmaceutical company's stock worth $359,000 after purchasing an additional 2,304 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.